Aeterna Zentaris (AEZS) Commences AEZS-108 Phase 2

November 12, 2012 7:33 AM EST Send to a Friend
Aeterna Zentaris Inc. (Nasdaq: AEZS) announced the start of the Phase 2 portion of its ongoing Phase 1/2 study in castration- and taxane-resistant prostate cancer (CRPC) with AEZS-108. The trial on the Company's targeted cytotoxic luteinizing hormone-releasing hormone (LHRH) analog, AEZS-108, is being supported by a three-year US$1.6 million grant from the National Institutes of Health to Jacek Pinski, MD, PhD, Associate Professor of Medicine at the Norris Comprehensive Cancer Center of the University of Southern California.

Preliminary data for the Phase 1 portion of this trial, presented in February 2012 at the American Society of Clinical Oncology Genitourinary Cancers Symposium, demonstrated that AEZS-108 was well tolerated and demonstrated early evidence of antitumor activity in men with CRPC. The poster on these preliminary data can be viewed on line through the following link. Final Phase 1 data are expected to be presented at an upcoming conference in 2013.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Add Your Comment